The relevance of IL-2 in potentiating anti-tumor activity of Tα1 in combination with cyclophosphamide was further evidenced in mouse model of Lewis lung carcinoma, where depletion of T cells abolished the positive response to combination therapy (159). Here, IL2 is linked to neoplasm.